Publications by authors named "Ylenia Cendon"
Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysis of two prospective studies in mCRPC patients treated with docetaxel. CTCs were measured at baseline and 3-6 weeks post treatment initiation.
View Article and Find Full Text PDFOver the past years, several studies have demonstrated that defects in DNA damage response and repair (DDR) genes are present in a significant proportion of patients with prostate cancer. These alterations, particularly mutations in BRCA2, are known to be associated with an increased risk of developing prostate cancer and more aggressive forms of the disease. There is growing evidence that certain DDR gene aberrations confer sensitivity to poly-(ADP ribose) polymerase inhibitors and/or platinum chemotherapy, while other defects might identify cases that are more likely to benefit from immune checkpoint inhibition.
View Article and Find Full Text PDFPurpose: Germline mutations in DNA damage repair (DDR) genes are identified in a significant proportion of patients with metastatic prostate cancer, but the clinical implications of these genes remain unclear. This prospective multicenter cohort study evaluated the prevalence and effect of germline DDR (gDDR) mutations on metastatic castration-resistance prostate cancer (mCRPC) outcomes.
Patients And Methods: Unselected patients were enrolled at diagnosis of mCRPC and were screened for gDDR mutations in 107 genes.
Background: Despite most metastatic castration-resistant prostate cancer (mCRPC) patients benefit from abiraterone acetate plus prednisone 5 mg bid (AA + P), resistance eventually occurs. Long-term use of prednisone has been suggested as one of the mechanisms driving resistance, which may be reversed by switching to another steroid.
Methods: SWITCH was a single-arm, open-label, single-stage phase II study.
Article Synopsis
- The study focuses on how the mTORC1 pathway plays a crucial role in cancer cell growth by regulating polyamine dynamics, which are vital for tumor development.
- Researchers used metabolomics on mouse models and human prostate cancer biopsies, discovering that mTORC1 alters the production of key metabolites like dcSAM and affects the stability of the enzyme AMD1.
- Findings show that high AMD1 levels correlate with active mTORC1 in human prostate cancer, while patients treated with the mTORC1 inhibitor everolimus experienced reduced AMD1 levels and cell proliferation, highlighting mTORC1's role in oncogenic metabolism.